Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Musa Yilmaz

Showing results (111-120 of 160) with videos related to

Pageof 16
Sort By:
Blood Neoplasia|September 22, 2025
Omacetaxine and venetoclax in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome with mutant RUNX1Courtney D DiNardo, Wei-Ying Jen, Guillermo Montalban-Bravo, et al.
Leukemia & Lymphoma|September 21, 2020
Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia - a distinct subtype with favorable prognosisMusa Yilmaz, Hagop M Kantarjian, Gokce Toruner, et al.
Blood Cancer Journal|May 2, 2022
Hypomethylating agent and venetoclax with FLT3 inhibitor "triplet" therapy in older/unfit patients with FLT3 mutated AMLMusa Yilmaz, Hagop Kantarjian, Nicholas J Short, et al.
The Lancet. Haematology|April 28, 2022
Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort studyCurtis A Lachowiez, Patrick K Reville, Hagop Kantarjian, et al.
The Lancet. Oncology|January 21, 2018
Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 studyHagop Kantarjian, Farhad Ravandi, Nicholas J Short, et al.
Blood Advances|April 7, 2020
Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimensCurtis A Lachowiez, Sanam Loghavi, Tapan M Kadia, et al.
Haematologica|May 2, 2024
Outcomes and genetic dynamics of acute myeloid leukemia at first relapseAlex Bataller, Hagop Kantarjian, Alexandre Bazinet, et al.
Cancer|September 8, 2016
Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemiaElias Jabbour, Nicholas J Short, Jeffrey L Jorgensen, et al.
American Journal of Hematology|September 2, 2022
Clinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience measurable residual disease (MRD) recurrence following MRD-negative remissionNicholas J Short, Walid Macaron, Tapan Kadia, et al.
The Lancet. Haematology|March 7, 2024
Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 studyAlexandre Bazinet, Guillermo Garcia-Manero, Nicholas Short, et al.
Pageof 16

Showing results (111-120 of 160) with videos related to

Sort By:
Pageof 16
Blood Neoplasia|September 22, 2025
Omacetaxine and venetoclax in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome with mutant RUNX1Courtney D DiNardo, Wei-Ying Jen, Guillermo Montalban-Bravo, et al.
Leukemia & Lymphoma|September 21, 2020
Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia - a distinct subtype with favorable prognosisMusa Yilmaz, Hagop M Kantarjian, Gokce Toruner, et al.
Blood Cancer Journal|May 2, 2022
Hypomethylating agent and venetoclax with FLT3 inhibitor "triplet" therapy in older/unfit patients with FLT3 mutated AMLMusa Yilmaz, Hagop Kantarjian, Nicholas J Short, et al.
The Lancet. Haematology|April 28, 2022
Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort studyCurtis A Lachowiez, Patrick K Reville, Hagop Kantarjian, et al.
The Lancet. Oncology|January 21, 2018
Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 studyHagop Kantarjian, Farhad Ravandi, Nicholas J Short, et al.
Blood Advances|April 7, 2020
Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimensCurtis A Lachowiez, Sanam Loghavi, Tapan M Kadia, et al.
Haematologica|May 2, 2024
Outcomes and genetic dynamics of acute myeloid leukemia at first relapseAlex Bataller, Hagop Kantarjian, Alexandre Bazinet, et al.
Cancer|September 8, 2016
Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemiaElias Jabbour, Nicholas J Short, Jeffrey L Jorgensen, et al.
American Journal of Hematology|September 2, 2022
Clinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience measurable residual disease (MRD) recurrence following MRD-negative remissionNicholas J Short, Walid Macaron, Tapan Kadia, et al.
The Lancet. Haematology|March 7, 2024
Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 studyAlexandre Bazinet, Guillermo Garcia-Manero, Nicholas Short, et al.
Pageof 16